Scarica l'app Stockscreener
26.18
0.00%
0.00
Pre-mercato:
26.18
Spyglass Pharma Inc Borsa (SGP) Ultime notizie
Latham & Watkins Advises on SpyGlass Pharma’s US$150 Million Initial Public Offering - Legal Desire Media and Insights
SpyGlass Pharma Closes $172.5 Million IPO - marketscreener.com
SpyGlass Pharma closes $172.5 million IPO on NASDAQ - Investing.com
Late-stage drugmaker SpyGlass Pharma raises $172.5M in IPO - stocktitan.net
Opening Day: SpyGlass Pharma soars in debut after strongly priced IPO - TipRanks
SpyGlass Pharma Raises $150 Million in Initial Public Offering - VisionMonday.com
SpyGlass Pharma Inc (SGP): Med-Tech Vision Pays Off: SpyGlass Pharma IPO Pops on Day One - Smartkarma
SpyGlass Pharma, Developer of Long-Acting Ocular Drug-Delivery Implants for Glaucoma and Other Chronic Eye Conditions, Files for Nasdaq Global Select Market IPO - TradingView
Eye Care Firm SpyGlass Pharma Soars 50% After $150 Million IPO - bloomberg.com
SpyGlass Pharma and Agomab's Contrasting Nasdaq Debuts - intellectia.ai
Spyglass Pharma shares surge 50% in Nasdaq debut By Investing.com - Investing.com Canada
Eye care firm SpyGlass Pharma soars 50% after $150 million IPO - MSN
SpyGlass Pharma Rings the Opening Bell - Nasdaq
SpyGlass Pharma Raises $150 Million in IPO for Eye Condition Treatments - intellectia.ai
SpyGlass Pharma raises $150 million in IPO priced at $16 per share - Investing.com
SpyGlass Pharma Prices $150 Million IPO - marketscreener.com
SGP IPO NewsChronic eye condition biotech SpyGlass Pharma prices IPO at $16 midpoint - renaissancecapital.com
Wilson Sonsini Advises SpyGlass Pharma on $150 Million IPO - Wilson Sonsini
SpyGlass Pharma prices IPO at $16 per share, raising $150 million - Investing.com Nigeria
SpyGlass Pharma announces pricing of IPO at $16.00 per share - marketscreener.com
Spyglass Pharma Announces Pricing Of IPO At $16.00 Per Share - TradingView
Late-stage biopharma SpyGlass Pharma to debut on Nasdaq after $150M IPO - stocktitan.net
SpyGlass Pharma Announces Pricing of Initial Public Offering - GlobeNewswire
IPO Rating: Spyglass Pharma Inc. - Smartkarma
SpyGlass Pharma Sets Terms for IPO as Ophthalmology-Focused Biotech Advances Sustained-Release Platform - Smartkarma
SpyGlass Pharma, Inc. (SGP): Glaucoma Care Biotech Sets Terms for IPO, Joins Heavy Issuance Week - Smartkarma
First Look | SpyGlass Pharma (Pending:SGP) - Seeking Alpha
SpyGlass Pharma, Inc. (SGP): Peeking at the IPO Prospectus Of Company Transforming Glaucoma Care - Smartkarma
SpyGlass Pharma Announces First Patients Randomized in SGP-005 and SGP-006, Two Registrational Phase III Clinical Trials of Its Novel BIM-IOL System - GlobeNewswire
SpyGlass Pharma Files $100M IPO - Orange County Business Journal
Eye Care-Focused Biopharma Firm SpyGlass Files for US IPO - bloomberg.com
SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer - GlobeNewswire
SpyGlass Pharma Announces Positive 36-Month First-in-Human - GlobeNewswire
Bimatoprost drug pad-IOL system shows reduction in mean IOP at 24 months - Ophthalmology Times
SpyGlass Pharma Appoints Anand Sundaram as Head of Commercial - GlobeNewswire
SpyGlass Pharma Raises $75M Series D Round - Orange County Business Journal
SpyGlass Pharma secures $75m for ophthalmic drug delivery platform - Pharmaceutical Technology
SpyGlass Pharma raises $75M for drug delivery platform - Drug Delivery Business
SpyGlass Pharma Presents 18-Month Data Demonstrating - GlobeNewswire
SpyGlass Pharma Completes Enrollment in Phase I/II Study of - GlobeNewswire
SpyGlass Posts Positive Early Data in IOL Clinical Trial - Orange County Business Journal
SpyGlass Pharma unveils 1-year data of drug delivery platform implanted during routine cataract surgery in patients diagnosed with glaucoma - Ophthalmology Times
SpyGlass Pharma Completes $90 Million Series C Financing to Advance Novel Treatments for Glaucoma and other Chronic Ophthalmic Diseases - PRWeb
SpyGlass Pharma releases 6-month data from first-in-human trial for glaucoma - Eyes On Eyecare
0.10%
7.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):